Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial
- PMID: 8985019
- DOI: 10.1016/s0360-3016(96)00430-0
Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial
Abstract
Purpose: To report the final results of a prospective randomized trial that aimed to evaluate efficacy and toxicity of concomitant postoperative radiotherapy and Cisplatin infusion in patients with Stage III or IV squamous cell carcinoma of the head and neck and histological evidence of extracapsular spread of tumor in lymph node metastase(s).
Methods and materials: Radiotherapy was delivered using a daily dose of 1.7 Gy for the first 54 Gy and 1.8 to 2 Gy until the completion of the treatment. Cisplatin 50 mg i.v. with forced hydratation was given or not every week (i.e., seven to nine cycles) concurrently with radiotherapy. A total of 44 patients were treated by irradiation only (RT group) and 39 by irradiation with chemotherapy (CM group).
Results: The RT group displayed a higher rate of loco-regional failures as compared to CM group (41 vs. 23%; p = 0.08). The overall survival, the survival corrected for deaths by intercurrent disease, and the disease-free survival were better in CM group as compared to RT group with statistically significant differences. Survival without loco-regional treatment failure was better in the CM group, the difference being close to the level of significance (p = 0.05). Survival without distant metastases were comparable in the two therapeutic groups. Ten severe late complications were observed, four in the RT group (17%) and six in the CM group (22%). Cox univariate analysis confirmed the importance of the therapeutic modality in predicting the overall survival, the survival corrected for deaths by intercurrent disease, and the disease-free survival.
Conclusions: The present final report of this phase III study confirms preliminary results. The concomitant use of 50 mg weekly Cisplatin infusion and postoperative radiation improved loco-regional control and survival. No significant increase of late radiation complications was observed in the CM group.
Similar articles
-
Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: preliminary report of a randomized trial.Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):243-6. doi: 10.1016/0360-3016(91)90098-o. Int J Radiat Oncol Biol Phys. 1991. PMID: 1991685 Clinical Trial.
-
Radical radiotherapy with concurrent weekly cisplatin in loco-regionally advanced squamous cell carcinoma of the head and neck: a single-institution experience.Head Neck Oncol. 2009 Jun 15;1:17. doi: 10.1186/1758-3284-1-17. Head Neck Oncol. 2009. PMID: 19527507 Free PMC article.
-
Conventional radiotherapy with concurrent weekly Cisplatin in locally advanced head and neck cancers of squamous cell origin - a single institution experience.Asian Pac J Cancer Prev. 2013;14(11):6883-8. doi: 10.7314/apjcp.2013.14.11.6883. Asian Pac J Cancer Prev. 2013. PMID: 24377620 Clinical Trial.
-
[Comparison of concomitant radiotherapy and chemotherapy with radiotherapy alone in advanced cancers of the head and neck: results of a randomized trial].Bull Cancer Radiother. 1996;83(2):97-103. Bull Cancer Radiother. 1996. PMID: 8688226 Review. French.
-
Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1247-53. doi: 10.1016/s0360-3016(02)04401-2. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654434 Review.
Cited by
-
Novel Strategies for the Bioavailability Augmentation and Efficacy Improvement of Natural Products in Oral Cancer.Cancers (Basel). 2022 Dec 30;15(1):268. doi: 10.3390/cancers15010268. Cancers (Basel). 2022. PMID: 36612264 Free PMC article. Review.
-
Locally advanced head and neck cancer.Curr Treat Options Oncol. 2001 Feb;2(1):7-13. doi: 10.1007/s11864-001-0012-x. Curr Treat Options Oncol. 2001. PMID: 12057136 Review.
-
State-of-the-art management of locally advanced head and neck cancer.Br J Cancer. 2005 Apr 25;92(8):1341-8. doi: 10.1038/sj.bjc.6602510. Br J Cancer. 2005. PMID: 15846296 Free PMC article. Review.
-
Concurrent chemoradiotherapy in head and neck cancer.Curr Oncol Rep. 1999;1(2):105-9. doi: 10.1007/s11912-999-0020-8. Curr Oncol Rep. 1999. PMID: 11122806 Review.
-
Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy.Front Oncol. 2021 Sep 6;11:727433. doi: 10.3389/fonc.2021.727433. eCollection 2021. Front Oncol. 2021. PMID: 34552878 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical